trending Market Intelligence /marketintelligence/en/news-insights/trending/qjgpczkicbqpdpffukccsq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Arena Pharmaceuticals prices common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Arena Pharmaceuticals prices common stock offering

Arena Pharmaceuticals Inc. priced an underwritten public offering of 8.5 million common shares at $41.50 each.

The company expects to raise gross proceeds of about $352.8 million through the offering, which is expected to close March 26, subject to customary closing conditions.

The underwriters have a 30-day option to buy up to an additional 1,275,000 shares at the offering price.

Arena Pharmaceuticals plans to use net proceeds to develop its clinical candidates and for general corporate purposes.

Citigroup, Leerink Partners, Cantor Fitzgerald, Credit Suisse and RBC Capital Markets are acting as joint book-running managers for the offering, with Guggenheim Securities and JMP Securities as co-managers.

San Diego-based Arena Pharmaceuticals develops small molecule drugs for various therapeutic areas in the U.S. and Switzerland.